ScripChina’s retaliatory tariffs mean the option of manufacturing US-originated drugs in China is making more sense than ever, at least to some local partners of US pharmaceutical companies. China imposed
ScripEarly development of CDK2 inhibitors has been beset with tolerability problems, particularly ocular and hematological, but new data for two products suggest that headway is being made for some candida
ScripIDRx, Inc is hoping to use its latest round of venture capital funding to advance its drug IDRX-42 to tackle a sarcoma subtype, gastrointestinal stromal tumor (GIST), that remains underserved despite
Pink SheetExperts in expanded access programs gave a glimpse of the difficulties in getting investigational drugs to patients, from helping physicians navigate the process to budgeting funds to pay for the prog